2-Methyl and 3-methylterrylenes have been obtained by Suzuki coupling of 3-bromoperylene and corresponding methylnaphthylboronic acids or esters, giving methylnaphthylperylene isomers, followed by Scholl cyclodehydrogenation; the latter reaction gave also the other cyclodehydrogenation isomers 10(respectively, 9-) methylbenzo[4,5]indeno[1,2,3-cd]perylene. (C) 2012 Elsevier Ltd. All rights reserved.
2-Methyl and 3-methylterrylenes have been obtained by Suzuki coupling of 3-bromoperylene and corresponding methylnaphthylboronic acids or esters, giving methylnaphthylperylene isomers, followed by Scholl cyclodehydrogenation; the latter reaction gave also the other cyclodehydrogenation isomers 10(respectively, 9-) methylbenzo[4,5]indeno[1,2,3-cd]perylene. (C) 2012 Elsevier Ltd. All rights reserved.
Michael Reaction Inspired Atroposelective Construction of Axially Chiral Biaryls
作者:Shengyi Yan、Wang Xia、Shaoyu Li、Qiuling Song、Shao-Hua Xiang、Bin Tan
DOI:10.1021/jacs.0c01963
日期:2020.4.22
biaryl atropisomers was established using a novel BINOL-derived phosphoramidite as chiral ligand. A broad range of atropisomeric biaryls were obtained in good efficiency and the practicality of this approach was verified by versatile transformations towards axially chiral ligands, catalysts, and other functional atropisomers. This set of catalytic systems successfully inhibited the routine 1,2 addition
Correction to “Michael Reaction Inspired Atroposelective Construction of Axially Chiral Biaryls”
作者:Shengyi Yan、Wang Xia、Shaoyu Li、Qiuling Song、Shao-Hua Xiang、Bin Tan
DOI:10.1021/jacs.0c05283
日期:2020.6.3
at 15 °C for 24 h. Isolated yields are provided, and er values were determined by chiral HPLC. The reaction proceeded for 2 days. PPh3 (2.0 equiv) was added, and the mixture was stirred for 4 h after the completion of the reaction. The reaction proceeded for 5 days. Figure 2. (a) Gram-scale synthesis of 3 and (b) preparation and (c) transformations of 4. Reagents and conditions: (a) AcCl, Et3N, CH2Cl2
[EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE TET2
申请人:[en]NOVARTIS AG
公开号:WO2023214325A1
公开(公告)日:2023-11-09
The present invention relates to novel pyrazolopyrimidine compounds that are TET2 inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by a TET2 inhibitor.